Jan. 11, 2018
by Andrii Buvailo
Biopharma insight
With all the hot discussions (for instance, here, here, here and here) going on right now among medicinal chemists, pharmaceutical …
Jan. 2, 2018
by Alfred Ajami
Biopharma insight
Effective drug discovery begins with the right assay, but the definition of "right" will shift as technology advances. More often …
Dec. 11, 2017
by Alfred Ajami
Biopharma insight
Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is …
Dec. 6, 2017
by Alfred Ajami
Biopharma insight
The16th century alchemical and 19th century science fiction revival of a miniature human being in a test tube is undergoing …
Nov. 22, 2017
by Alfred Ajami, Andrii Buvailo
Biopharma insight
Choosing the right biological target or a combination of targets is a fundamental task for any successful drug discovery project. …
Nov. 22, 2017
by Alfred Ajami
Biopharma insight
The question is often raised, but the answer remains to be uncovered because the definition of drug "target" continues to …
Nov. 14, 2017
by Andrii Buvailo
Biopharma insight
In this interview, Dr. Jackie Hunter, CEO at BenevolentAI, provides insights into how the company’s AI-driven platform helps scientists create …
Nov. 13, 2017
by Alfred Ajami
Biopharma insight
Consensus seems universal and the news about it flows literally by the minute over gene editing as a future therapy, …
Nov. 6, 2017
by Alfred Ajami
Biopharma insight
Pharma productivity has remained a daunting challenge, notably because R&D departments have been shuffled and reorganized over the last few …
Oct. 27, 2017
by Alfred Ajami
Biopharma insight
In a case of "back to the future", chemists at Scripps collaborating with instrument engineers at IKA have unveiled a …
Sept. 24, 2017
by Andrii Buvailo
Biopharma insight
Boston-based LifeMine Therapeutics, a fresh new drug discovery startup, just announced a $55 million Series A financing from a number …
Aug. 21, 2017
by BiopharmaTrend
Biopharma insight
This is an interview with Niels Iversen Møller, a CEO, and Co-founder of Evaxion Biotech -- an immuno-informatics biotech from …